EECP Treatment Significantly Improved Clinical and Some Biochemical Parameters in Symptomatic CAD and Chronic HF Patients 體外反搏顯著改善冠狀動脈疾病(CAD)和心臟衰竭(HF)患者的臨床和生化指標

Source From 資料來源 : https://pubmed.ncbi.nlm.nih.gov/22366105/

EECP Treatment Significantly Improved Clinical and Some Biochemical Parameters in Symptomatic CAD and Chronic HF Patients

OBJECTIVE:

Enhanced external counterpulsation (EECP) is a noninvasive treatment that is proven safe and effective in patients with coronary artery disease (CAD) and heart failure (HF). The aims of this study are to investigate the clinical effects of EECP therapy in patients with symptomatic CAD and chronic HF, and to find out an answer to the question: Does EECP therapy have any effect on the prognostic markers of HF?

METHODS:

This study was designed as a prospective cohort study. A total of 68 consecutive patients with symptomatic CAD and chronic HF referred to EECP therapy were enrolled in this study between November 2007 and December 2010; 47 patients (39 males and 8 females, 65 ± 7, years), have undergone EECP treatment, and 21 patients (20 males and 1 female, 62 ± 10 years), who did not want to participate in the EECP program comprised the control group. Statistical analysis was performed using t tests for dependent and independent samples, Mann-Whitney U test, Chi-square and Fischer exact tests.

RESULTS:

EECP therapy resulted in significant Improvement in post-intervention New York Heart Association functional class (p<0.001), left ventricular ejection fraction (p<0.001), B-type natriuretic peptide levels (p<0.003), uric acid levels (p<0.05), free-T3/free-T4 ratio (p<0.034) and mitral annular E (p<0.05) velocity, compared with baseline, a finding not evident in the control group.

CONCLUSION:

EECP treatment significantly improved clinical and some biochemical parameters, which are mostly prognostic markers in patients with symptomatic CAD and chronic HF.

「增強體外反搏治療對缺血性心力衰竭患者的 臨床效果 」

目標

體外反搏(EECP)是一種非侵入性治療方法,已被證明對冠狀動脈疾病(CAD)和心臟衰竭(HF)患者安全有效。本研究的目的是調查EECP治療對有症狀的CAD和慢性HF患者的 臨床效果 ,並回答以下問題:EECP治療是否對HF的預後標誌物有任何影響?

方法

本研究設計為前瞻性的同期研究。在2007年11月至2010年12月期間,共有68名連續有症狀CAD和慢性HF患者接受EECP治療並納入本研究;其中47名患者接受了EECP治療,而21名患者不願參加EECP計劃,作為對照組。統計分析採用因變數和獨立樣本 t 檢驗、曼-惠特尼 U 檢驗、卡方核對總和費舍爾精確檢驗。

結果

與基線相比,EECP治療明顯改善了紐約心臟協會功能分級,左心室射血分數、B型利尿肽水準、尿酸水準、遊離T3/遊離T4比值和二尖瓣環E速度,而對照組中則沒有明顯改善。

結論

EECP治療顯著改善了有症狀的CAD和慢性HF患者的臨床和一些生化指標,這些指標大多是預後的標誌。

×